Tag Archives: Iain MacLeod

Aldatu Licenses Technology from Harvard

One Step Closer to Affordable HIV DrugResistance Test

By Martha Henry

Harvard recently entered into a licensing agreement with Aldatu Biosciences for exclusive use of the PANDAA technology. Using PANDAA, Aldatu, a biotech start-up based at LabCentral in Cambridge, is developing a rapid HIV drug-resistance test for patients failing first-line antiretroviral therapy (ART).

Continue reading

Fast, Cheap & Sensitive: HAI Researchers Invent Improved Drug Resistance Test

Greg Price, Iain MacLeod, Hann-Shuin Yew, David Raiser, winners of the $40,000 Deans’ Challenge photo by Evgenia Eliseeva/Eve Photography
Greg Price, Iain MacLeod, Hann-Shuin Yew, David Raiser, winners of the $40,000 Deans’ Challenge photo by Evgenia Eliseeva/Eve Photography

By Martha Henry

Over 12 million people are currently taking antiretroviral (ARV) treatment for HIV. That number is expected to rise to 15 million by 2015. An unfortunate consequence of the global scale up of treatment is an increase in drug resistance, which can render a drug regimen ineffective.

About 10% of people fail treatment ever year. In areas like southern Africa, where the burden of HIV is greatest, the cost of drug resistance testing is prohibitively high. “There is a need for cost-effective, efficient techniques for the detection of HIV drug resistance,” said Dr. Mark Wainberg, Director of the McGill University AIDS Centre and an expert on HIV drug resistance. Continue reading